rilzabrutinib

FDA Drug Profile — WAYRILZ

Drug Details

Generic Name
rilzabrutinib
Brand Names
WAYRILZ
Application Number
NDA219685
Sponsor
Sanofi S.r.l.
NDC Codes
2
Dosage Forms
TABLET, FILM COATED
Routes
ORAL
Active Ingredients
RILZABRUTINIB

Indications and Usage

1 INDICATIONS AND USAGE WAYRILZ is indicated for the treatment of adult patients with persistent or chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment. WAYRILZ is a kinase inhibitor indicated for the treatment of adult patients with persistent or chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment. ( 1 )